T. Rowe Price Investment Management
DNTH icon

T. Rowe Price Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

T. Rowe Price Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379M Buy
3,888,456
+2,596,274
+201% +$227M 0.25% 108
2026
Q1 		$108M Buy
+1,292,182
New +$74.8M 0.07% 240

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Investment Management's DNTH Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Dianthus Therapeutics (DNTH) stake by 201% in Q2 2026, buying an estimated $227M and bringing the position to 3,888,456 shares worth $379M. The position accounts for 0.25% of the portfolio, ranked #108.

T. Rowe Price Investment Management first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • T. Rowe Price Investment Management held 3,888,456 shares of Dianthus Therapeutics worth $379M as of Q2 2026.
  • T. Rowe Price Investment Management bought 2,596,274 Dianthus Therapeutics shares in Q2 2026, an estimated $227M.
  • Dianthus Therapeutics made up 0.25% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #108 holding.
  • T. Rowe Price Investment Management first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.